Price Sarah, Wiering Bianca, Mounce Luke T A, Hamilton Willie, Abel Gary
Medical School, College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter EX1 2LU, UK.
Medical School, College of Medicine and Health, University of Exeter, St Luke's Campus, Heavitree Road, Exeter EX1 2LU, UK.
Cancer Epidemiol. 2023 Feb;82:102310. doi: 10.1016/j.canep.2022.102310. Epub 2022 Dec 9.
Current methods for estimating the timeliness of cancer diagnosis are not robust because dates of key defining milestones, for example first presentation, are uncertain. This is exacerbated when patients have other conditions (multimorbidity), particularly those that share symptoms with cancer. Methods independent of this uncertainty are needed for accurate estimates of the timeliness of cancer diagnosis, and to understand how multimorbidity impacts the diagnostic process.
Participants were diagnosed with oesophagogastric cancer between 2010 and 2019. Controls were matched on year of birth, sex, general practice and multimorbidity burden calculated using the Cambridge Multimorbidity Score. Primary care data (Clinical Practice Research Datalink) was used to explore population-level consultation rates for up to two years before diagnosis across different multimorbidity burdens. Five approaches were compared on the timing of the consultation frequency increase, the inflection point for different multimorbidity burdens, different aggregated time-periods and sample sizes.
We included 15,410 participants, of which 13,328 (86.5 %) had a measurable multimorbidity burden. Our new maximum likelihood estimation method found evidence that the inflection point in consultation frequency varied with multimorbidity burden, from 154 days (95 %CI 131.8-176.2) before diagnosis for patients with no multimorbidity, to 126 days (108.5-143.5) for patients with the greatest multimorbidity burden. Inflection points identified using alternative methods were closer to diagnosis for up to three burden groups. Sample size reduction and changing the aggregation period resulted in inflection points closer to diagnosis, with the smallest change for the maximum likelihood method.
Existing methods to identify changes in consultation rates can introduce substantial bias which depends on sample size and aggregation period. The direct maximum likelihood method was less prone to this bias than other methods and offers a robust, population-level alternative for estimating the timeliness of cancer diagnosis.
目前用于评估癌症诊断及时性的方法并不可靠,因为关键定义节点的日期,例如首次就诊日期并不确定。当患者患有其他疾病(共病),尤其是那些与癌症有共同症状的疾病时,这种情况会更加严重。需要独立于这种不确定性的方法来准确评估癌症诊断的及时性,并了解共病如何影响诊断过程。
参与者在2010年至2019年期间被诊断为食管胃癌。对照组根据出生年份、性别、全科医疗以及使用剑桥共病评分计算的共病负担进行匹配。利用初级保健数据(临床实践研究数据链),探讨不同共病负担情况下诊断前长达两年的人群层面咨询率。对五种方法在咨询频率增加的时间、不同共病负担的拐点、不同汇总时间段和样本量方面进行了比较。
我们纳入了15410名参与者,其中13328名(86.5%)有可测量的共病负担。我们新的最大似然估计方法发现,咨询频率的拐点随共病负担而变化,从无共病患者诊断前的154天(95%可信区间131.8 - 176.2),到共病负担最重患者的126天(108.5 - 143.5)。使用替代方法确定的拐点在多达三个负担组中更接近诊断时间。样本量减少和改变汇总时间段导致拐点更接近诊断时间,最大似然方法的变化最小。
现有的识别咨询率变化的方法可能会引入很大的偏差,这取决于样本量和汇总时间段。直接最大似然方法比其他方法更不容易出现这种偏差,并为估计癌症诊断的及时性提供了一种可靠的、人群层面的替代方法。